Clin2
NCT07139067Possibly a fitRecruiting

YK1101 for advanced solid tumors

Advanced Solid Tumor Cancer

Part of Cancer clinical trials.

This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
10 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have a genetic type called HLA-A*11:01
  • Your tumor must have a protein called MAGE-A4 (tested on a sample)
  • You must have advanced cancer that has not responded to or cannot take standard therapy
  • You must be between 18 and 75 years old
  • You must have at least one tumor that can be measured on scans

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07631793Recruiting· Phase 1
Experimental vaccine for advanced solid tumors

This trial tests an experimental vaccine called YKYY031 for people with advanced solid tumors that have stopped responding to standard treatments. The vaccine aims to help your immune system fight cancer cells that carry specific markers. It may be an option if you have certain genetic markers and tumor proteins.

Beijing, Beijing Municipality
NCT07412665Not yet recruiting· Early Phase 1
Immune cell study for advanced solid tumors

This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.

Beijing
NCT07482319Not yet recruiting· Phase 1
Immune cell therapy for advanced solid tumors that have not responded to treatment

This trial tests an experimental treatment called GK01, which uses your own immune cells (called tumor-infiltrating lymphocytes) that have been taken from your tumor, multiplied in a lab, and given back to you. It is for people with advanced solid tumors that have not responded to standard treatments, and aims to see if these cells can shrink your cancer.

Beijing
NCT06364501Not yet recruiting· Phase 1
Testing a new targeted drug for advanced solid tumors

This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.

Beijing, Beijing Municipality
NCT07704515Not yet recruiting· Phase 1
Cell therapy for advanced solid tumors

This trial tests an investigational cell therapy called GKL-006Allo for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can help shrink or slow the growth of tumors.

Beijing, Beijing Municipality
NCT06170294Recruiting· Phase 1
MAGE-A4 TCR-T therapy for advanced solid tumors

This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.

Beijing, Beijing Municipality

Hear when a new Advanced Solid Tumor Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.